The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Open accessAbstract
We report on a series of N-pyrazole, N'-aryl ureas and their mode of binding to p38 mitogen activated protein kinase. Importantly, a key binding domain that is distinct from the adenosine 5'-triphoshate (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein. We describe the correlation of the structure-activity relationships and crystallographic structures of these inhibitors with p38. In addition, we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site. This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of 45 (BIRB 796) as a clinical candidate for the treatment of inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Keys, J. R., Land vatter, S. W., et al. (1994) · Nature · doi:10.1038/372739a0 · Cited by 3,288
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
The p38 signal transduction pathway Activation and function
Ono, K., & Han, J. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(99)00071-6 · Cited by 1,571
Crystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 833
Self-citationGauche effect. Stereochemical consequences of adjacent electron pairs and polar bonds
Wolfe, S. (1972) · Accounts of Chemical Research · doi:10.1021/ar50051a003 · Cited by 782
p38 MAPK signalling cascades in inflammatory disease
Herlaar, E., & Brown, Z. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01544-0 · Cited by 564
Badger, A. M., Bradbeer, J. N., Votta, B., Lee, J. C., Adams, J. L., & Griswold, D. E. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21307-6 · Cited by 499
Inhibition of p38 MAP kinase as a therapeutic strategy
Lee, J. C., Kumar, S., Griswold, D. E., Underwood, D. C., Votta, B. J., & Adams, J. L. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00206-x · Cited by 455
A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
Tong, L., Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Brown, M. L., & Pargellis, C. A. (1997) · Nature Structural Biology · doi:10.1038/nsb0497-311 · Cited by 387
Self-citationp38 Mitogen-Activated Protein Kinase Inhibitors— Mechanisms and Therapeutic Potentials
Lee, J. C., Kassis, S., Kumar, S., Badger, A., & Adams, J. L. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00008-x · Cited by 348
Branger, J., van den Blink, B., Weijer, S., Madwed, J., Bos, C. L., Gupta, A., Yong, C.-L., Polmar, S. H., Olszyna, D. P., Hack, C. E., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.4070 · Cited by 233
Self-citationLiverton, N. J., Butcher, J. W., Claiborne, C. F., Claremon, D. A., Libby, B. E., Nguyen, K. T., Pitzenberger, S. M., Selnick, H. G., Smith, G. R., Tebben, A., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9805236 · Cited by 196
Etanercept: A Review of its Use in Rheumatoid Arthritis
Jarvis, B., & Faulds, D. (1999) · Drugs · doi:10.2165/00003495-199957060-00014 · Cited by 171
RWJ 67657, a Potent, Orally Active Inhibitor of p38 Mitogen-Activated Protein Kinase
Wadsworth, S. A., CAVENDER, D. E., Beers, S. A., Lalan, P., Schafer, P. H., Malloy, E. A., Wu, W., Fahmy, B., Olini, G. C., Davis, J. E., et al. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35155-9 · Cited by 157
Dinarello, C. A. (1991) · Current Opinion in Immunology · doi:10.1016/s0952-7915(05)80018-4 · Cited by 150
2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis
Gallagher, T. F., Fier-Thompson, S. M., Garigipati, R. S., Sorenson, M. E., Smietana, J. M., Lee, D. M., Bender, P. E., Lee, J. C., Laydon, J. T., Griswold, D. E., et al. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00189-z · Cited by 133
Boehm, J. C., Smietana, J. M., Sorenson, M. E., Garigipati, R. S., Gallagher, T. F., Sheldrake, P. W., Bradbeer, J. N., Badger, A. M., Laydon, J. T., Lee, J. C., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960415o · Cited by 123
Pyrroles and other heterocycles as inhibitors of P38 kinase
de Laszlo, S. E., Visco, D. M., Agarwal, L., Chang, L. L., Chin, J., Croft, G. F., Forsyth, A., Fletcher, D. S., Frantz, B., Hacker, C., et al. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00495-8 · Cited by 121
Adams, J. L., Boehm, J. C., Kassis, S., Gorycki, P. D., Webb, E. F., Hall, R., Sorenson, M. E., Lee, J. C., Ayrton, A. D., Griswold, D. E., et al. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00549-6 · Cited by 114
Adams, J. L., Boehm, J. C., Gallagher, T. F., Kassis, S., Webb, E. F., Hall, R., Sorenson, M. E., Garigipati, R. S., Griswold, D. E., & Lee, J. C. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00570-4 · Cited by 107
Etanercept: therapeutic use in patients with rheumatoid arthritis
Garrison, L., & McDonnell, N. D. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.2008.i65 · Cited by 106
Clinical economics review: medical management of inflammatory bowel disease
WARD, Bodger, K., DALY, & Heatley (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00437.x · Cited by 105
Fijen, J. W., Zijlstra, J. G., Boer, P. D., Spanjersberg, R., Tervaert, J.-W. C., van der Werf, T. S., Ligtenberg, J. J. M., & Tulleken, J. E. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01485.x · Cited by 101
Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases
Salituro, F. G., Germann, U. A., Wilson, K. P., Bemis, G. W., Fox, T., & Su, M. S. S. (1999) · Current Medicinal Chemistry · doi:10.2174/092986730609220401150415 · Cited by 87
McLay, I. M., Halley, F., Souness, J. E., McKenna, J. M., Benning, V., Birrell, M. A., Burton, B., Belvisi, M. G., Collis, A. J., Constan, A. A., et al. (2001) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00331-x · Cited by 86
Boehm, J. C., & Adams, J. L. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.1.25 · Cited by 80
Potential of p38 inhibitors in the treatment of rheumatoid arthritis.
Foster, M., Halley, F., & Souness, J. (2000) · PubMed · Cited by 71
Protein kinase inhibitors: emerging pharmacophores 1997 - 2000
Dumas, J. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.3.405 · Cited by 71
Cytokines in rheumatoid arthritis: trials and tribulations
Carteron, N. L. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01757-3 · Cited by 59
Review article: efficacy of infliximab in Crohn’s disease — induction and maintenance of remission
Rutgeerts, P. J. (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00025.x · Cited by 53
Ukaji, F., Kitajima, I., Kubo, T., Shimizu, C., Nakajima, T., & Maruyama, I. (1999) · Annals of the Rheumatic Diseases · doi:10.1136/ard.58.3.169 · Cited by 45
Crystallization and preliminary crystallographic analysis of recombinant human p38 MAP kinase
Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Hopkins, J., Brown, M. L., Pargellis, C. A., Tong, L., & Davidson, W. S. (1997) · Protein Science · doi:10.1002/pro.5560060126 · Cited by 17
Self-citation
Cited by
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057
Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., & Mainz, D. T. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051256o · Cited by 6,851
Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases
Cargnello, M., & Roux, P. P. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00031-10 · Cited by 3,274
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
The Many Roles of Computation in Drug Discovery
Jorgensen, W. L. (2004) · Science · doi:10.1126/science.1096361 · Cited by 1,554
Metadata
- Authors
- Regan, J., Breitfelder, S., Cirillo, P., Gilmore, T., Graham, A. G., Hickey, E., Klaus, B., Madwed, J., Moriak, M., Moss, N., Pargellis, C., Pav, S., Proto, A., Swinamer, A., Tong, L., & Torcellini, C.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-05-25
- Volume
- 45
- Issue
- 14
- Pages
- 2994-3008
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2135133228
- Cited by
- 348
- References
- 35
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.